{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:39:17Z","timestamp":1789763957357,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Novartis Gene Therapies. Grant Number:PS2031"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1038\/s41434-022-00339-0","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T01:02:28Z","timestamp":1651021348000},"page":"101-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Adeno-associated virus serotype 9 antibody titers in patients with SMA pre-screened for treatment with onasemnogene abeparvovec \u2013routine care evidence"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7255-6276","authenticated-orcid":false,"given":"Sharon","family":"Aharoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Bistritzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liora","family":"Sagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Fattal-Valevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Ginzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Noyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rony","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Nevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"339_CR1","doi-asserted-by":"publisher","unstructured":"Messina S, Sframeli M. New treatments in spinal muscular atrophy: positive results and new challenges. J. Clin. Med. 2020;9. https:\/\/doi.org\/10.3390\/jcm9072222.","DOI":"10.3390\/jcm9072222"},{"key":"339_CR2","first-page":"39","volume":"10","author":"M J\u0119drzejowska","year":"2020","unstructured":"J\u0119drzejowska M. Advances in newborn screening and presymptomatic diagnosis of spinal muscular atrophy. Degener Neurol Neuromuscul Dis. 2020;10:39\u201347.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"339_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet EJHG. 2012;20:27\u201332.","journal-title":"Eur J Hum Genet EJHG"},{"key":"339_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-med-070119-115459","volume":"72","author":"B Ravi","year":"2021","unstructured":"Ravi B, Chan-Cort\u00e9s MH, Sumner CJ. Gene-targeting therapeutics for neurological disease: lessons learned from spinal muscular atrophy. Annu Rev Med. 2021;72:1\u201314.","journal-title":"Annu Rev Med"},{"key":"339_CR5","doi-asserted-by":"crossref","unstructured":"Sproule DM, Al-Zaidy SA, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW et al. AVXS-101 phase 1 gene therapy clinical trial in SMA type 1: experience with pre-existing anti-AAV9 antibody in the SMA1 population (S13.001). Neurology. 2017; 88. https:\/\/n.neurology.org\/content\/88\/16_supplement\/s13.001. Accessed 17 Feb 2021.","DOI":"10.1212\/WNL.88.16_supplement.S13.001"},{"key":"339_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2017","unstructured":"Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2017;8:87\u2013104.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"339_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","volume":"21","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Mercuri E, Swoboda KJ, Menier M, van Olden R, et al. Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec. Mol Ther Methods Clin Dev. 2021;21:76\u201382.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"339_CR8","unstructured":"Food and Drug Adminstration Zolgensma. 2021. https:\/\/www.fda.gov\/media\/126109\/download."},{"key":"339_CR9","unstructured":"FDA Press release. FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. FDA. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease."},{"key":"339_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cca.2020.09.024","volume":"510","author":"S Park","year":"2020","unstructured":"Park S, Lee H, Shin S, Lee S-T, Lee K-A, Choi JR. Analytical validation of the droplet digital PCR assay for diagnosis of spinal muscular atrophy. Clin Chim Acta. 2020;510:787\u20139.","journal-title":"Clin Chim Acta"},{"key":"339_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/hgtb.2018.131","volume":"29","author":"U Kavita","year":"2018","unstructured":"Kavita U, Dai Y, Salvador L, Miller W, Adam LP, Levesque PC, et al. Development of a chemiluminescent ELISA method for the detection of total anti-adeno associated virus serotype 9 (AAV9) antibodies. Hum Gene Ther Methods. 2018;29:237\u201350.","journal-title":"Hum Gene Ther Methods"},{"key":"339_CR12","unstructured":"Israeli Ministry of Health. Vaccine briefing. 2021. https:\/\/health.gov.il\/UnitsOffice\/HD\/PH\/epidemiology\/td\/docs\/tadrich_Chisunim.pdf."},{"key":"339_CR13","doi-asserted-by":"crossref","unstructured":"Ali HG, Ibrahim K, Elsaid MF, Mohamed RB, Abeidah MIA, Al Rawwas AO et al. Gene therapy for spinal muscular atrophy: the Qatari experience. Gene Ther. 2021;28:676\u201380.","DOI":"10.1038\/s41434-021-00273-7"},{"key":"339_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/infdis\/161.3.487","volume":"161","author":"J Van Savage","year":"1990","unstructured":"Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis. 1990;161:487\u201392.","journal-title":"J Infect Dis"},{"key":"339_CR15","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1016\/j.vaccine.2007.06.020","volume":"25","author":"E Leuridan","year":"2007","unstructured":"Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine. 2007;25:6296\u2013304.","journal-title":"Vaccine"},{"key":"339_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/mus.27363","volume":"64","author":"EA Kichula","year":"2021","unstructured":"Kichula EA, Proud CM, Farrar MA, Kwon JM, Saito K, Desguerre I, et al. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve. 2021;64:413\u201327.","journal-title":"Muscle Nerve"},{"key":"339_CR17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21:704\u201312.","journal-title":"Hum Gene Ther"},{"key":"339_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/humc.2017.109","volume":"28","author":"H Fu","year":"2017","unstructured":"Fu H, Meadows AS, Pineda RJ, Kunkler KL, Truxal KV, McBride KL, et al. Differential prevalence of antibodies against adeno-associated virus in healthy children and patients with mucopolysaccharidosis iii: perspective for AAV-mediated gene therapy. Hum Gene Ther Clin Dev. 2017;28:187\u201396.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"339_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","volume":"100","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy SA, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol. 2019;100:3\u201311.","journal-title":"Pediatr Neurol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00339-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:49:38Z","timestamp":1727052578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-022-00339-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":19,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1038\/s41434-022-00339-0","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"8 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SA has received clinical trial funding from AveXis\/Novartis Gene Therapies and Biogen and has served on scientific advisory boards for AveXis\/Novartis Gene Therapies. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Institutional Review Boards of the four Medical Centers. All analyses were performed on anonymized data. The approval for the study was provided by the local ethics committees, including at the Schneider Medical Center (RMC-0519-20); Tel Aviv Medical Center (TLV-873-18), Wolfson Medical Center (WOMC-0053-21), and Soroka Medical Center (SOR-0109-21).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}